Aptevo (APVO) Director Daniel Abdun‑Nabi Converts 400 RSUs to Stock

What Happened
Daniel Abdun‑Nabi, a director of Aptevo Therapeutics (APVO), converted vested restricted stock units (RSUs) into common shares on August 6, 2026. The Form 4 shows 400 shares acquired via exercise/conversion of a derivative (code M) and a simultaneous entry reporting 400 shares disposed at $0.00. Footnotes state RSUs convert one-for-one into common stock and that the RSUs were originally granted on August 6, 2025 and vested on the first anniversary.

Key Details

• Transaction date: August 6, 2026 (reported on Form 4 filed Aug 10, 2026).
• Reported transactions: 400 shares acquired (derivative conversion, code M); 400 shares disposed at $0.00 (derivative). No dollar value shown for the acquisition.
• Footnotes: F1 — RSUs convert one-for-one to common stock; F2 — grant was 8/6/2025 (7,200 pre-split / 400 post-split) with vesting on the first anniversary.
• Shares owned after transaction: not specified in the provided filing details.
• Filing timeliness: Form 4 filed Aug 10 for an Aug 6 transaction (4 days later). Form 4s are generally due within two business days, so this filing was submitted after that typical window.

Context
The filing reflects conversion of vested RSUs into common stock (a non‑market purchase). The paired $0.00 disposal line often appears when shares are surrendered to cover taxes or fees, though this particular Form 4 does not explicitly state the reason for the $0.00 disposition. This type of RSU conversion is routine for vested awards and does not by itself indicate a buy or sell opinion by the insider.